The FDA approved Opdualag on the strength of the ... BMS' notoriously hard to tolerate CTLA4 checkpoint inhibitor – which has been approved as a monotherapy for melanoma since 2011 and as ...

Checkpoint Therapeutics’ late entry into the PD-1/PD-L1 inhibitor category ... or labelling issues with the drug, and Checkpoint has said it hopes to re-apply for approval swiftly.

A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC.

Qfitlia (fitusiran) is the first therapy for both hemophilia A or B, with or without inhibitors, available in the United ...

Nivolumab and ipilimumab combination approved ... of dual checkpoint inhibition in MSI-H/dMMR metastatic CRC. This review was conducted as part of Project Orbis, an initiative of the FDA’s ...

Patients with advanced Merkel cell carcinoma had significant increases in survival rates following FDA approval of immune checkpoint inhibitors.

A supplemental biologics license application has been submitted to the FDA for nogapendekin alfa plus Bacillus ...

The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the first-line treatment of adult patients with unresectable or metastatic ...

CTLA4 Inhibitors Market forecast to 2035 covers market size, key trends, competitive landscape, and growth opportunities in cancer immunotherapy and autoimmune diseases.

Drs Ursula A. Matulonis and Gini F. Fleming discuss the state of endometrial cancer, the role of immunotherapy, and ...

Despite the absence of any approved VISTA inhibitors to date, a growing body of research underscores the potential of targeting this immune checkpoint as a novel approach to overcome tumor immune ...